The study, which analysed NHS health record data on over seven million adults found protection in older adults aged over 65 years, and in clinically vulnerable adults.
Researchers from Bristol Medical School and HDR UK South-West sought to investigate how quickly vaccine effectiveness waned over time in adults without prior SARS-CoV-2 infection and who received two doses of BNT162b2 (Pfizer-BioNTech) or ChAdOx1 (AstraZeneca) COVID-19 vaccine compared with unvaccinated individuals.
Using linked GP, hospital, and COVID-19 records on 1,951,866 and 3,219,349 adults who had received two doses of BNT162b2 and ChAdOx1, respectively and 2,422,980 unvaccinated adults, researchers were able to provide a clearer picture of vaccine effectiveness against COVID-19 hospital admission, COVID-19 death, and positive SARS-CoV-2 test.
Rates of COVID-19 hospital admission and COVID-19 death were substantially lower among vaccinated than unvaccinated adults up to six months after their second dose. Vaccine effectiveness against these events was found to be at least 80% for BNT162b2, and at least 75% for ChAdOx1. However, waning vaccine effectiveness against infection with SARS-CoV-2 meant that rates in vaccinated individuals were similar to or higher than in unvaccinated individuals by six months after the second dose.
Dr Elsie Horne, Senior Research Associate in Medical Statistics and Health Data Science in Bristol Medical School: Population Health Sciences (PHS) and the study’s lead author, said: “Until now there has been limited and conflicting evidence relating to the rate of waning following second dose of COVID-19 vaccines, whether it extends to severe COVID-19, and whether the rate differs according to age and clinical vulnerability.
“Although we found that protection against severe COVID-19 provided by two doses of vaccine wanes over time, the very high initial protection means that, despite waning, protection remains high six months after the second dose. This finding was consistent across all adults, including older adults and those who are at risk of severe COVID-19.”
Jonathan Sterne, Professor of Medical Statistics and Epidemiology in Bristol Medical School: PHS, Director of the National Institute for Health and Care Research Bristol Biomedical Research Centre (NIHR Bristol BRC), Director of Health Data Research UK (HDR UK) South-West and co-author, added: “We found that the rate at which vaccine effectiveness waned was consistent across subgroups defined by age and clinical vulnerability. Studying how long COVID-19 vaccines remain effective continues to be important to scheduling and targeting of booster vaccinations.”
The researchers now plan to lead a follow-up study looking at vaccine effectiveness to one year post-second dose and into the era of the Omicron variant. They are also investigating the rate of waning in vulnerable clinical subgroups, such as those with chronic kidney disease and with cancer.
The study was supported by two COVID-19 National Core Studies (NCS) programmes: COVID-19 Longitudinal Health and Wellbeing and COVID-19 Data and Connectivity; Asthma UK; NIHR (National Institute for Health and Care Research) and Wellcome. TPP provided technical expertise and infrastructure pro bono in the context of a national emergency.
Risk of blood clots remains for almost a year after COVID-19 infection, study suggests
20 September 2022
COVID-19 infection increases the risk of potentially life-threatening blood clots for at least 49 weeks, according to a new study of health records of 48 million unvaccinated adults from the first...
The COALESCE study’s primary aim is to provide both the UK and the devolved governments with the information necessary to actionably improve COVID-19 vaccine uptake and coverage.